Enanta Pharmaceuticals (ENTA) revenue and earnings history
Enanta Pharmaceuticals reported revenue of $63M for fiscal 2026 (year ended Sep 30, 2026), −3.6% on the year before, and net income of −$68.2M.
Over 15 years, from fiscal 2011 to fiscal 2026, revenue grew at a compound rate of +2.8% a year.
Revenue and net income, 16 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026ended Sep 30, 2026 | $63M−3.6% | −$62.4M | −$68.2M | −$42.6M | $206K | −$42.8M | $14M | — | — | $20.3M | — | 10-K |
| 2025ended Sep 30, 2025 |
The latest quarter, insider trades and fund moves: Enanta Pharmaceuticals (ENTA) on OQRO.
Common questions
What was Enanta Pharmaceuticals's revenue in fiscal 2026?
$63M for the year ended Sep 30, 2026, as reported in its 10-K filed Nov 18, 2026. That is −3.6% on fiscal 2025 ($65.3M).
How fast has Enanta Pharmaceuticals's revenue grown?
From $41.9M in fiscal 2011 to $63M in fiscal 2026: a compound annual growth rate of +2.8% over 15 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Enanta Pharmaceuticals tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
